

**FORM 51-102F3**  
**MATERIAL CHANGE REPORT**

**Item 1. Name and Address of Company**

Abattis Biologix Corporation  
Suite 310 - 885 Dunsmuir St.  
Vancouver BC V6C 1N5

Phone: 778-908-6650 Fax: 604-538-6658

**Item 2. Date of Material Change**

February 17, 2012

**Item 3. News Release**

A News Release dated and issued February 17, 2012 at Vancouver, British Columbia, through Canada Stockwatch, Market News and SEDAR.

**Item 4. Summary of Material Change**

See news release, a copy of which is attached hereto.

**Item 5. Full Description of Material Change**

See news release, a copy of which is attached hereto.

**Item 6. Reliance on subsection 7.1(2) or (3) of National Instrument 51-102**

Not applicable.

**Item 7. Omitted Information**

Not applicable.

**Item 8. Executive Officer**

Mike Withrow, President & CEO  
Telephone: 778-908-6650

**Item 9. Date of Report**

February 17, 2012

Suite 310 – 885 Dunsmuir St  
Vancouver, BC V6C 1N5  
Tel: 778-908-6650  
Fax: 604-538-6658



---

**Abattis Announces Cancellation of 10,250,000 Shares  
Pursuant to Termination of ZITEK Licensing Agreement**

**February 17, 2012** – Vancouver, British Columbia – Abattis Biologix Corporation (the “Company” or “Abattis”) (CNSX: FLU) is pleased to announce that further to the termination of the Company’s agreement with the Hensley Group Inc. (see the Company’s news release of January 24, 2012), 10,250,000 common shares previously issued in relation to the agreement were surrendered to the Company and were cancelled and returned to treasury effective February 17, 2012.

Prior to the shares being surrendered the company had 61,937,900 issued and outstanding. The new issued and outstanding is 51,687,900.

**About Abattis Biologix Corporation**

Abattis Biologix Corporation is a specialty bio-technology life sciences company that has acquired intellectual property, conducts research, and works to develop proprietary health and wellness solutions that address chronic illnesses and disease in animals and humans through proprietary and patent pending formulations. The company has identified targeted channels to market and license proprietary patent pending products throughout the world.

**ON BEHALF OF THE COMPANY**

“Yazan Al Homsí”  
Yazan Al Homsí  
Director

For information please contact:  
**Hamza Thindal Capital Corp.**  
P: 888.371.9098  
F: 888.371.9099  
E: [info@htcapitalcorp.com](mailto:info@htcapitalcorp.com)  
<http://htcapitalcorp.com>

Neither the CNSX Exchange nor its regulations services accepts responsibility for the adequacy or accuracy of this release.